Live
- DEO suspends teacher accused of sexual assault
- PM ‘cursing’ Congress out of despair: Maharashtra Cong Chief
- Applications are invited for Junior Colleges Scheme District Scheduled Castes Development Officer Ramlal
- A nomination was filed on the second day for the Nagar Kurnool parliamentary seat
- SP Gaikwad inspected the Telangana Amarnath Saleswaram Jatara yatra arrangements
- Rahul Gandhi's decision to contest from Wayanad shows 'lack of confidence': BJP President Nadda
- IPL 2024: Delhi bowlers will go after all of SRH’s top-order batters, says head coach Ricky Ponting
- At Amroha rally, PM Modi sends out ‘meaningful’ message for Muslims and Hindus
- Tripura records highest 79.83 pc voter turnout in Northeast
- The government has to clear the confusion
Dr Reddy's teams up with BIRAC
Dr Reddy’s teams up with BIRAC
To speed up Sputnik V vaccine clinical trials in India
Hyderabad: City-based global drug major Dr Reddy's Laboratories Ltd on Thursday announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology (DBT), for advisory support on clinical trials of Sputnik V vaccine in India.
The latest tie up with BIRAC will allow Dr Reddy's to identify and use in clinical trial centres for the vaccine, which are funded under the National Biopharma Mission (NBM), implemented by Project Management Unit-NBM at BIRAC.
Satish Reddy, chairman, Dr Reddy's Laboratories, said: "We're pleased with the collaboration with BIRAC as an advisory partner for clinical trials of the Sputnik V vaccine in India. We look forward to working with them to accelerate our efforts in bringing the vaccine to India."
Dr Renu Swarup, secretary, DBT, and Chairperson, BIRAC, adds: "The government is committed to fast track clinical development of Covid-19 vaccine candidates and provide facilitation to accelerate market readiness of a suitable vaccine. We at DBT look forward to this partnership with Dr Reddy's for this Indo Russian Collaboration for Vaccine Development." Further, the company will have access to Good Clinical Laboratory Practice (GCLP) labs to conduct immunogenicity assay testing of the vaccine.
